Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose CRB4101 Tablets in Healthy Adult Subjects
Latest Information Update: 15 Dec 2022
At a glance
- Drugs CRB 4101 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors CR Pharmaceutical
- 15 Dec 2022 New trial record